Agenus
AGENAlgoritmens signaler
- ›Starkt 3m-momentum (+91.8%)
- ›Starkt 6m-momentum (+150.8%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (157% årlig)
- ›+177% från 52v-botten
- ›Ökad handelsvolym (+1243%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsAGEN|Agenus Inc|Price:6.600|Chg%:+0.470 - TradingKey
4 d sedanAGEN|Agenus Inc|Price:6.600|Chg%:+0.470 TradingKey
TradingKeyAgenus plans August webcast on BOT+BAL colon cancer trial - Stock Titan
5 d sedanAgenus plans August webcast on BOT+BAL colon cancer trial Stock Titan
Stock TitanAGENUS INC SEC Filing (Jul 28, 2026) - Stock Titan
5 d sedanAGENUS INC SEC Filing (Jul 28, 2026) Stock Titan
Stock TitanAgenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing - Yahoo Finance
2026-07-17Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing Yahoo Finance
Yahoo FinanceAgenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - Yahoo Finance
2026-07-14Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? Yahoo Finance
Yahoo FinanceAgenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) - Yahoo Finance
2026-07-13Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) Yahoo Finance
Yahoo FinanceAGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment - TradingView
2026-07-13AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment TradingView
TradingViewWhy Is Agenus Stock Gaining Monday? - Benzinga
2026-07-13Why Is Agenus Stock Gaining Monday? Benzinga
BenzingaAgenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
2025-11-19Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session wi
AgenusBusiness WireAgenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
2025-11-18Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias w
AgenusBusiness WireAgenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
2025-11-10Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate acce
AgenusBusiness WireAgenus to Provide Corporate Update and Third Quarter 2025 Financial Report
2025-11-05Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 1
AgenusBusiness WireAgenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
2025-10-17Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1 i
AgenusBusiness WireAgenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
2025-10-16Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leadin
AgenusBusiness WireFrance Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
2025-09-09Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory m
AgenusBusiness WireAgenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-05Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10,
AgenusBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.